Bispecific Trial in Myeloma Sparks Talks of 'Functional Cure'

Combination treatment shows large improvement in survival for people with relapsed myeloma

At the American Society of Hematology Conference in Orlando, new results from the MajesTEC-3 study show that combining teclistamab with daratumumab could help people with myeloma whose cancer has come back or hasn't responded to previous treatment, to live longer without their cancer getting worse.

Bispecific Trial in Myeloma Sparks Talks of 'Functional Cure'

(MedPage Today) -- ORLANDO -- Combining teclistamab (Tecvayli) with subcutaneous daratumumab-hyaluronidase (Darzalex Faspro) significantly improved progression-free survival (PFS) and overall survival (OS) in patients with relapsed/refractory...

J&J’s ‘remarkable’ Tecvayli data support earlier use in multiple myeloma

In a step forward for bispecific antibodies, study results presented at ASH suggest a Tecvayli-based combination could have curative potential early in a patient’s disease course.

Teclistamab Plus Daratumumab Significantly Improves Survival in R/R Myeloma | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

The MajesTEC-3 trial showed that teclistamab combined with subcutaneous daratumumab improved overall survival vs standard daratumumab-based regimens in relapsed/refractory multiple myeloma.

Teclistamab/SC Daratumumab Potential New SOC in 2L R/R Multiple Myeloma

Teclistamab plus subcutaneous daratumumab yielded significant improvement in efficacy for patients with R/R multiple myeloma.